Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2026)
Monopar Therapeutics (MNPR) posted Operating Expenses of $4.1 million for Q3 2025, up 26.55% sequentially from $3.2 million in Q2 2025, and up 159.89% YoY from $1.6 million in Q3 2024.
Monopar Therapeutics (MNPR) Operating Expenses (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported Operating Expenses for 9 years, with the latest figure at $4.1 million in Q3 2025.
- Quarterly Operating Expenses rose 159.89% year-over-year to $4.1 million in Q3 2025, while the trailing twelve-month figure through Dec 2025 was $10.5 million (up 59.7% YoY) and the FY2024 annual result came in at $4.6 million, changed N/A from the prior year.
- Operating Expenses improved to $4.1 million in Q3 2025 per MNPR's latest filing, from $3.2 million in the prior quarter.
- Over five years, Operating Expenses peaked at $4.1 million in Q3 2025 and troughed at $1.5 million in Q4 2024.
- A 5-year average of $2.4 million and a median of $2.4 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses tumbled 31.75% in 2024, then soared 159.89% in 2025.
- Over 5 years, Operating Expenses stood at $2.7 million in 2021, then grew by 8.5% to $2.9 million in 2022, then slipped by 28.98% to $2.1 million in 2023, then decreased by 26.49% to $1.5 million in 2024, then jumped by 169.52% to $4.1 million in 2025.
- According to Business Quant data, Operating Expenses over the past three periods registered $4.1 million, $3.2 million, and $3.2 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | 6.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.64 Mn |
| Sep 30, 2025 | 4.09 Mn |
| Jun 30, 2025 | 3.23 Mn |
| Mar 31, 2025 | 3.22 Mn |
| Dec 31, 2024 | 1.52 Mn |
| Sep 30, 2024 | 1.57 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Sep 30, 2023 | 2.07 Mn |
| Jun 30, 2023 | 2.33 Mn |
| Mar 31, 2023 | 2.53 Mn |
| Dec 31, 2022 | 2.91 Mn |
| Sep 30, 2022 | 2.41 Mn |
| Jun 30, 2022 | 2.76 Mn |
| Mar 31, 2022 | 2.46 Mn |
| Dec 31, 2021 | 2.68 Mn |
| Sep 30, 2021 | 2.46 Mn |
| Jun 30, 2021 | 2.09 Mn |
| Mar 31, 2021 | 1.89 Mn |
| Dec 31, 2020 | 2.26 Mn |